Sodium borate

DB14505ApprovedSmall molecule

No FDA- or EMA-approved therapeutic indications on its own.

Mechanism: Information regarding the mechanism of action of boric acid in mediating its antibacterial or antifungal actions is limited. Boric acid inhibits biofilm formation and hyphal transformation of Candida albicans, which are critical virulence factors. In addition, arrest of fungal growth was observed with the treatment of boric acid.
Curator reviewed · 2 references
Primary indication: No FDA- or EMA-approved therapeutic indications on its own.Curator reviewed · 5 structured indications
Formula / weight: B₄Na₂O₇ · 201.219 g/mol (avg)
First approval: Canada, 1997
Also known as: Borax

Resolves to

Compound

UNII8191EN8ZMDCAS1330-43-4

Clinical / RWD

RxNorm36680ATCS01AX07

Structure

InChIKeyUQGFMSUEHSUPRD-UHFFFAOYSA-NSMILES[Na+].[Na+].[O-]B1OB2OB([O-])OB(O1)O2

Targets

P19440GGT1

Transporters

Q8NBS3SLC4A11

What you can answer from here — as of September 12, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1TransporterSubstrate / inhibitor direction, not just membership

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

5Structured indicationsCondition, population, route and combination as fields, not prose

30Marketed productsAcross 4 countries and 24 labellers

1ATC codeIncluding every combination product, plus 8 drug categories

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sodium borate, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In